Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany
- Partnership between LumiraDx and Axonlab will allow Axonlab to sell the unique LumiraDx Point of Care testing solution and give LumiraDx the ability to expand the reach of the LumiraDx Platform and tests.
- The agreement combines Axonlab’s strong, direct and established commercial network with LumiraDx´s state-of-the-art rapid diagnostic system, allowing a wider range of customers and patients to benefit from the capabilities of the product.
- The LumiraDx Platform already allows high sensitivity testing of NT-proBNP, HbA1c, CRP, D-Dimer, INR, Flu A/B, RSV and SARS-CoV-2 while further tests including molecular assays and a high-sensitivity Troponin I test are in final stages of development.
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that it signed a commercial distribution agreement with Axon Lab AG (“Axonlab”) for the commercialization of its LumiraDx Platform and diagnostic tests to include exclusive distribution rights in Switzerland and additional non-exclusive distribution rights in further European countries to include and starting in Germany. Under the terms of the distribution agreement, LumiraDx has granted Axonlab the right to promote, market, and sell the LumiraDx Platform and tests to hospitals, doctors, clinics, private laboratories and research institutions in the aforementioned countries. The distribution agreement is effective immediately. LumiraDx will continue its direct sales programs in its many active markets across the globe.
Axonlab has dedicated diagnostics franchises and direct offices in the countries covered under the distribution agreement and is well positioned to accelerate the commercial success of the LumiraDx Platform in Switzerland and Germany.
“We are excited to partner with LumiraDx for the commercial distribution of the LumiraDx Platform in Switzerland and Germany,” said Lukas Hadorn CEO of Axonlab. “LumiraDx clearly has shown to have a unique technology with a broad, attractive menu of diagnostic rapid tests, on an intuitive and simple to use instrument, which allows these key tests to be performed in doctors’ offices, clinics, and other testing sites at the point-of-care. The LumiraDx Platform matches well into Axonlab’s broad portfolio of point-of-care diagnostic solutions. In addition to offering a diversified portfolio, Axonlab places great emphasis on partnership-based customer relationships. We respond individually to the needs of our customers and always strive to implement segment specific solutions that suit best for all parties involved.”
David Walton, LumiraDx’s Chief Commercial Officer commented “We are pleased to announce our new partnership with Axonlab, whose track record has shown that they are a fantastic partner for us in these markets. With the new distribution agreement for Switzerland and Germany, the Axonlab collaboration adds two important markets to our distribution portfolio and will allow us to accelerate the commercial roll-out of our unique LumiraDx Platform. LumiraDx already has a strong commercial presence, either directly or through our distribution partners, and we plan to continue expanding this worldwide network through the addition of such major commercial partnerships.”
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
